The Latest Cardiac and Vascular News
HANGZHOU, China, Sept. 10, 2020 /PRNewswire/ — The leading transcatheter heart valve medical device player in China – Venus Medtech (Hangzhou) Inc. (“Venus Medtech” or the “Company”, together with its subsidiaries, the “Group”, stock code: 2500) and Jilin Changchun Haoyue Halal Meat Co., Ltd (“Haoyue Group“), are pleased to announce the establishment of a joint venture company, Venus Haoyue Medtech […]
EDEN PRAIRIE, Minn., Sept. 10, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced key takeaways from a recent webinar, where Dr. John L. Jefferies discussed the use of precision medicine for the treatment […]
Medtronic Receives Breakthrough Device Designation from FDA, Begins Early Feasibility Study for Investigational Intrepid™ Transcatheter Valve System for the Treatment of Tricuspid Valve Regurgitation DUBLIN, Sept. 9, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced U.S. Food and Drug Administration (FDA) approval of an early feasibility […]
WASHINGTON, Sept. 9, 2020 /PRNewswire/ — AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a new collaboration with the Centers for Disease Control and Prevention (CDC) and the CDC Foundation that aims to expand lipid testing in resource-limited countries. Improving access […]
BRISBANE, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere. Danicamtiv […]
Rule would give Medicare patients immediate access to breakthrough heart failure therapy MT. LAUREL, N.J.–(BUSINESS WIRE)–Impulse Dynamics, Inc., a company dedicated to improving the lives of people with heart failure, today announced that a proposed rule by the Centers for Medicare and Medicaid Services (CMS) could further streamline coverage of […]
RUC-4 is the first and only GPIIb/IIIa inhibitor that is in clinical development as a simple, single subcutaneous injection treatment to potently and rapidly block all platelet aggregation pathways to improve outcomes for heart attack patients September 03, 2020 09:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–CeleCor Therapeutics, Inc. announced positive […]
EDEN PRAIRIE, Minn., Sept. 03, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the company will host an interactive, physician-led webinar to discuss “Precision Medicine for the Treatment of Fluid Overload in Patients […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that the Company has resumed cases in the pivotal ALIVE Trial studying Less Invasive Ventricular Enhancement, or LIVE™ Therapy, using the Revivent TC™ Transcatheter Ventricular Enhancement System. The […]
VASCEPA is the first and only agent studied on top of statin therapy reported to exhibit coronary plaque regression in hypertriglyceridemic patients VASCEPA in REDUCE-IT® cardiovascular outcomes study achieved statistical significance for primary and secondary endpoints at predefined blinded first and second interim analyses that persisted at final analyses VASCEPA […]
